Actavis Hypertension Combo Prompts Discussion Of “Me-Too” Drug Standards
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee used much of its review of a nebivolol/valsartan combo pill to discuss how much of an improvement a “me-too” product should offer over predecessors and a minimum clinical benefit threshold for antihypertensives.
You may also be interested in...
Hypertension Drug Labeling Would Benefit From Responder Analysis
Advisory committee members say they’d feel better about approving combo products for hypertension if labeling included pivotal trial data enabling clinicians to assess how individual patients fared on therapy.
With Its Hypertension Franchise in Crisis, Novartis Restructures
Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.